Skip to main content
. 2017 May 17;8(46):80286–80294. doi: 10.18632/oncotarget.17925

Table 2. Tumor response in the study patients (n = 50).

No. of patients (%)
Primary site Overall
CR 5 (10) 1 (2)
PR 35 (70) 21 (42)
SD 4 (8) 11 (22)
PD 0 (0) 12 (24)
Not evaluable 6 (12) 5 (10)
Response (CR + PR) 40 (80) 22 (44)
Disease control (CR + PR + SD) 44 (88) 33 (66)